SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) – Analysts at Wedbush raised their Q1 2024 EPS estimates for SpringWorks Therapeutics in a research report issued to clients and investors on Tuesday, February 27th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($1.27) per share for the quarter, up from their […]